The University of Chicago Header Logo

Connection

Russell Z. Szmulewitz to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Drug Administration Schedule.
Russell Z. Szmulewitz
Connection Strength
0.037
Drug Administration Schedule
  1. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.